Eyenovia, Inc. (EYEN): Price and Financial Metrics
GET POWR RATINGS... FREE!
EYEN POWR Grades
- EYEN scores best on the Sentiment dimension, with a Sentiment rank ahead of 92.04% of US stocks.
- EYEN's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
- EYEN's current lowest rank is in the Momentum metric (where it is better than 5.04% of US stocks).
EYEN Stock Summary
- With a price/sales ratio of 32.9, Eyenovia Inc has a higher such ratio than 92.92% of stocks in our set.
- With a year-over-year growth in debt of 157.84%, Eyenovia Inc's debt growth rate surpasses 93.46% of about US stocks.
- As for revenue growth, note that EYEN's revenue has grown 100% over the past 12 months; that beats the revenue growth of 94.1% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Eyenovia Inc, a group of peers worth examining would be STRO, EDIT, ALPN, APYX, and ANAB.
- Visit EYEN's SEC page to see the company's official filings. To visit the company's web site, go to www.eyenoviabio.com.
EYEN Price Target
For more insight on analysts targets of EYEN, see our EYEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $15.50 | Average Broker Recommendation | 1.25 (Strong Buy) |
EYEN Stock Price Chart Interactive Chart >
EYEN Price/Volume Stats
| Current price | $5.44 | 52-week high | $7.72 |
| Prev. close | $5.40 | 52-week low | $2.55 |
| Day low | $5.32 | Volume | 45,300 |
| Day high | $5.47 | Avg. volume | 183,797 |
| 50-day MA | $5.09 | Dividend yield | N/A |
| 200-day MA | $4.86 | Market Cap | 140.66M |
Eyenovia, Inc. (EYEN) Company Bio
Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst that has completed Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat that has completed Phase II clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.
Latest EYEN News From Around the Web
Below are the latest news stories about Eyenovia Inc that investors may wish to consider to help them evaluate EYEN as an investment opportunity.
Eyenovia: Recent MicroLine Data, October MydCombi PDUFA Date Bode Well For Value CreationPhoto by Domepitipat/iStock via Getty Images Eyenovia (EYEN) is pursuing three ophthalmological opportunities. The first, pharmacologic mydriasis is a $250 million US market opportunity, and the company's drug, MydCombi, has an October 28, 2001 FDA PDUFA date. MicroLine, a pilocarpine formulation to treat presbyopia, will compete in the new market... |
Biotech Stock Roundup: MRNA's Vaccine Update & Pipeline Updates From REGN, BMYThe biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Regeneron (REGN), among others. |
Eyenovia Stock Shoots Higher on Positive MicroLine Data in Late-Stage Presbyopia StudyEyenovia Inc (NASDAQ: EYEN) has announced topline data from its VISION-1 Phase 3 study evaluating MicroLine, for the temporary improvement of near vision in adults with presbyopia. The results will be presented at a future ophthalmic-focused medical meeting. The study met its primary endpoint with a statistically significant proportion of subjects treated with MicroLine showing a three-line or more improvement in distance corrected near visual acuity versus placebo in low light conditions at two hours post-treatment. MicroLine was well-tolerated. All adverse events were mild, and there were no serious adverse events. Presbyopia is the age-related, progressive hardening of the eye's lens. "Along with plans for VISION-2 in the coming months, we continue to prepare for the potential FDA ap... |
Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of PresbyopiaPrimary endpoint was achieved with well-tolerated micro-array print (MAP™) safety profile Upcoming key 12 month milestones include Mydcombi PDUFA; Vision 2 Phase 3 trial results and completion of enrollment for CHAPERONE Phase 3 trial NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of MAP™ therapeutics, today announced that its VISION-1 study evaluating the company’s proprietary pilocarpine formulation, MicroLine, for the temporary improvement of near vision in adults with presbyopia, achieved its primary endpoint. Preparations are underway for a second Phase 3 registration study, VISION-2. These studies are required for FDA approval and will serve as the basis for a planned New Drug Ap... |
Eyenovia: Still A Great Long-Term Investment In OphthalmologyPhoto by Nes/E+ via Getty ImagesEyenovia (EYEN) is a biopharmaceutical company which specializes in ophthalmology products based on the company's piezo print technology, which are aimed at replacing current technologies and solutions. The company has several completed and Phase III trial solutions aimed at replacing macro-dosing like eye drops in... |
EYEN Price Returns
| 1-mo | 24.77% |
| 3-mo | -9.93% |
| 6-mo | 31.72% |
| 1-year | 74.92% |
| 3-year | -29.35% |
| 5-year | N/A |
| YTD | -10.23% |
| 2020 | 35.27% |
| 2019 | 57.19% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...